Ferumoxytol - AMAG Pharmaceuticals

Drug Profile

Ferumoxytol - AMAG Pharmaceuticals

Alternative Names: Feraheme; Ferrosoferric oxide; Rienso

Latest Information Update: 22 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AMAG Pharmaceuticals
  • Class Antianaemics; Contrast media; Diagnostic agents; Ferric compounds; Ferrous compounds; Heavy metals; Minerals
  • Mechanism of Action Iron replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Iron deficiency anaemia
  • Phase II Peripheral arterial disorders

Most Recent Events

  • 28 Mar 2018 AMAG Pharmaceuticals plans a new paediatric trial for Iron deficiency anaemia (in patients with chronic kidney disease) in USA (IV) in the second quarter of 2018
  • 09 Mar 2018 Phase-III clinical trials in Iron deficiency anaemia (In children) in Hungary (IV) (EudraCT2017-004026-15)
  • 05 Feb 2018 US FDA approves sNDA for label extension of Ferumoxytol for Iron deficiency anaemia in all patients with intolerance or unsatisfactory response to oral iron
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top